bims-imseme Biomed News
on Immunosenescence and T cell metabolism
Issue of 2026–09–20
43 papers selected by
Pierpaolo Ginefra, Ludwig Institute for Cancer Research



  1. Nat Immunol. 2026 Sep 11.
      CD8+ T cell dysfunction is a major obstacle to hepatitis B virus (HBV) clearance and antitumor immunity. Here, using a humanized mouse model, we identify a T cell receptor targeting a clinically relevant HBV epitope and reveal ANKRD11 as a key epigenetic regulator of CD8+ T cell dysfunction in chronic infection and tumors. Ankrd11 knockout in CD8+ T cells enhances HBV-specific T cell proliferation and effector differentiation, especially under immunosuppressive conditions, via AP-1 family gene upregulation. Loss of Ankrd11 both drives the conversion of progenitor exhausted T cells into terminally exhausted T cells, and reprograms PD-1-TOX- tolerant cells into functional effectors, improving antiviral and antitumor responses. Ankrd11-deficient T cells show increased granzyme and superior effector function, enhancing viral control and tumor regression. These findings position ANKRD11 as a promising immunotherapy target for chronic HBV infection and cancer.
    DOI:  https://doi.org/10.1038/s41590-026-02652-x
  2. Cancer Res. 2026 Sep 15.
      The aged tumor microenvironment can impair antitumor T cell function, but the molecular regulators that become limiting in this setting remain poorly defined. In a recent issue of Cell, Chen and colleagues harness in vivo CRISPR screening to compare the effects of genetic perturbations in tumor-reactive CD8+ T cells across young and aged hosts. The screen reveals that increased T cell persistence or an effector-like transcriptional state does not necessarily translate into improved tumor control and identifies Dusp5 and Zfp219 as distinct functional regulators. DUSP5 broadly restrains ERK-dependent proliferation, and its loss improves tumor control in both young and aged mice. ZFP219, by contrast, preferentially limits cytotoxicity in aged hosts; its deletion increases granzyme expression and improves tumor control specifically in the aged setting. Human tumor datasets show that ZNF219 expression in intratumoral CD8+ T cells increases with age and is associated with poorer clinical outcomes. Moreover, Zfp219 loss enhances the response to PD-1 blockade in aged mice, producing complete tumor clearance in a subset of animals and durable protection after rechallenge. Together, these findings show that host age can reshape the functional consequences of T cell perturbations and reveal age-dependent genetic vulnerabilities with potential therapeutic relevance.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-26-3854
  3. Sci Adv. 2026 Sep 18. 12(38): eaee8251
      Naïve T cells maintain quiescence yet must respond rapidly to antigens, but how they prime this capacity is unclear. We identify histone variant H2A.Z as a key regulator of an epigenetic training program that licenses quiescent naïve CD8+ T cells for future activation. H2A.Z deficiency disrupts naïve T cell homeostasis and effector responses. Multiomics reveals that H2A.Z is selectively deposited at oxidative phosphorylation (OXPHOS) gene promoters in quiescent naïve CD8+ T cells, priming the chromatin for rapid transcriptional induction. This training is developmentally instructed by tonic interleukin-7 (IL-7) signaling and regulated by transcription factor GABPα. Age-related decline in IL-7 signaling reduces H2A.Z occupancy and impairs T cell activation, while IL-7 supplementation or enforced H2A.Z expression rescues this defect. H2A.Z overexpression also enhances chimeric antigen receptor T cell stemness and antitumor efficacy. Our work defines an IL-7R-GABPα-H2A.Z-OXPHOS axis that epigenetically establishes metabolic and functional fitness in quiescent T cells, offering insights for immunotherapy targeting ageing and tumors.
    DOI:  https://doi.org/10.1126/sciadv.aee8251
  4. Int J Mol Sci. 2026 Aug 27. pii: 7664. [Epub ahead of print]27(17):
      The efficacy of adoptive cell transfer (ACT) therapy in solid tumors is often limited by the functional exhaustion and insufficient persistence of infused CD8+ T cells within the tumor microenvironment. Through the integrated analysis of single-cell transcriptomic data, this study identified enolase 1 (ENO1), a key rate-limiting enzyme in glycolysis, as a core gene highly correlated with the superior anti-tumor phenotype of tumor-infiltrating lymphocytes (TILs). However, in vitro functional validation demonstrated that the overexpression of Eno1 failed to substantially enhance the anti-tumor efficacy of mouse T cells, suggesting the presence of a downstream metabolic regulatory node within the glycolytic cascade that restricts the conversion of carbon flux. To overcome this limitation, we introduced the small molecule activator TEPP-46 to target a crucial downstream metabolic hub, pyruvate kinase M2 (PKM2). Transcriptome sequencing confirmed that PKM2 activation successfully induced systemic metabolic rewiring in CD8+ T cells and broadly upregulated the expression of cytotoxicity- and memory-related genes. In an in vivo B16-OVA melanoma model, OT-1 T cells subjected to In vitro TEPP-46 pretreatment exhibited significantly enhanced tumor-suppressive capabilities and effectively promoted the preferential differentiation of T cells into central memory T cells (Tcm). In summary, this study highlights the importance of targeting downstream metabolic nodes to bypass intrinsic metabolic restrictions in T cells. It demonstrates that in vitro metabolic pretreatment via PKM2 activation represents an effective translational strategy for optimizing the anti-tumor efficacy of ACT cell products.
    Keywords:  CD8+ T cells; adoptive cell transfer; enolase 1; glycolysis; metabolic reprogramming
    DOI:  https://doi.org/10.3390/ijms27177664
  5. Cell Rep Med. 2026 Sep 15. pii: S2666-3791(26)00468-4. [Epub ahead of print] 103051
      Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) induces durable responses in metastatic melanoma, yet the clonal and transcriptional dynamics governing tumor-reactive T cell fate during ex vivo expansion and after transfer remain poorly understood. Here, we perform longitudinal single-cell RNA and T cell receptor sequencing across five time points, from baseline tumors through two-phase ex vivo expansion to post-infusion blood and tumor biopsies, in seven melanoma patients, resolving both the CD8+ and CD4+ compartments. Tumor-reactive CD8+ T cells are reinvigorated from exhaustion and acquire HLA-II-high or KLF2-high profiles. We further dissect the tumor-responsive CD4+ compartment in depth, revealing lineage-dependent reinvigoration in which follicular helper T cells adopt an effector state while exhausted CD4+ T cells retain dysfunction. In non-responders, across three cohorts, co-transferred type 17 T cells and de novo regulatory T cell expansion after transfer associate with treatment failure. These data define subtype-specific signatures across both lineages to guide TIL expansion.
    Keywords:  T cell exhaustion; T cell receptor repertoire; adoptive cell therapy; cancer immunotherapy; follicular helper T cells; melanoma; regulatory T cells; tumor-infiltrating lymphocytes; tumor-reactive T cells; type 17 T cells
    DOI:  https://doi.org/10.1016/j.xcrm.2026.103051
  6. Front Immunol. 2026 ;17 1960808
      
    Keywords:  T cell activation and differentiation; T cell homeostasis; chronic inflammation; immune regulation; immune-mediated pathologies; regulatory T cells
    DOI:  https://doi.org/10.3389/fimmu.2026.1960808
  7. Front Immunol. 2026 ;17 1897839
      Sepsis is increasingly recognized as a dynamic immune disorder in which early hyperinflammation may coexist with or progress to profound immunosuppression. T-cell exhaustion is a central feature of this immune paralysis and is characterized by lymphopenia, impaired proliferation, reduced effector cytokine production, inhibitory receptor upregulation, metabolic dysfunction, and defective antibacterial immunity. Recent studies have expanded the mechanistic landscape of sepsis-induced T-cell exhaustion beyond the classical PD-1/PD-L1 axis. TIGIT-mediated suppression of CD4+ T-cell immunity, extracellular vesicle-associated PD-L1, TOX-independent exhaustion-like programming, dysregulated IL-17 production, mitochondrial dysfunction, and reduced glutaminase expression in CD4+ T cells have emerged as important mechanisms. These findings indicate that septic T-cell exhaustion is not a direct replica of exhaustion in cancer or chronic viral infection, but a context-dependent and potentially reversible immune dysfunction state. Biomarkers such as PD-1+CD3+ T cells, soluble PD-1/PD-L1, IL-7, TIGIT, EV-PD-L1, and GLS may support patient stratification and dynamic immune monitoring. Immune-reversal strategies, including PD-1/PD-L1 blockade, TIGIT inhibition, IL-7-based restoration, and metabolic reprogramming, require precise timing and individualized selection to restore host defense without aggravating inflammatory organ injury.
    Keywords:  PD-1/PD-L1; T-cell exhaustion; TIGIT; immune reversal; sepsis
    DOI:  https://doi.org/10.3389/fimmu.2026.1897839
  8. J Clin Invest. 2026 Sep 15. pii: e196445. [Epub ahead of print]136(18):
      Effector CD8+ T cells are key drivers of type 1 diabetes (T1D) pathogenesis, yet questions remain regarding the molecular defects leading to altered cytotoxicity, peripheral tissue phenotype, and receptor specificity. We analyzed human pancreatic lymph nodes (pLNs) using mass cytometry and single-cell RNA-seq (scRNA-seq) with combined T cell receptor (TCR) profiling. Cytometric analysis revealed enrichment of T stem cell memory-like (TSCM-like) cells (CD8+CD45RA+CD27+CD28+CCR7+CXCR3+) in T1D pLNs. scRNA-seq indicated an elevated inflammatory cytokine gene signature (IFITM3, LTB) along with regulators of terminal differentiation (BCL6, BCL3), coupled with downregulation of exhaustion-associated genes (DUSP2, NR4A2, TSC22D3) in CD8+ T cells in T1D pLNs. Immune response enrichment analysis (IREA) indicated IL-15 signaling as a significant driver of these phenotypes. Integrated TCR and transcriptomics analysis revealed a cluster of diverse naive-like CD8+ T cell clones in T1D pLNs. Comparison of pLNs and pancreatic tissue slice isolates indicated sharing of effector CD8+ T cells, with enhanced terminal effector signatures within the pancreas relative to paired pLNs. Multiplex imaging revealed differential localization of T cell factor 1 (TCF1)- and thymocyte selection-associated high mobility group box protein (TOX)-expressing T cells in the pancreas, with islet-proximal TCF1+TOX+ cells displaying a mixture of activation and exhaustion-associated phenotypes. Thus, we provide multimodal cellular profiles enriched in T1D tissues for consideration in therapeutic targeting.
    Keywords:  Autoimmunity; Diabetes; Immunology; T cells; Transcriptomics
    DOI:  https://doi.org/10.1172/JCI196445
  9. ACS Sens. 2026 Sep 12.
      T cell exhaustion has widespread implications for the progression and treatment of chronic diseases including tuberculosis, HIV, malaria, and cancer, yet current detection methods require expensive and tedious antibody labeling, destructive workflows, or days-long functional assays that limit dynamic monitoring capabilities. Here, we introduce Raman spectroscopy as a label-free assay for distinguishing T cell states directly from culture while preserving viability for downstream use. We leverage a 1-D convolutional neural network with sharpness aware minimization for machine learning-based spectral analysis, allowing us to identify critical Raman features for distinguishing exhausted T cells. We achieve >97% accuracy in discriminating unstimulated, activated, and exhausted T cells across three donors and multiple hardware setups, with >92% accuracy in identifying an intermediate activation-exhaustion transition state. We identify vibrational modes associated with alterations in nucleic acids and lipids as key features that distinguish T cell activation and exhaustion. In heterogeneous populations, we quantify exhaustion percentage with R2 = 1 and strong correlation to adenine (r = -0.91) and amide II protein (r = 0.94) vibrational modes. This work establishes vibrational fingerprinting as a direct measure of T cell exhaustion beyond surface marker expression toward scalable immune diagnostics, in-line monitoring, and selective immunopheresis.
    Keywords:  Raman spectroscopy; T cell exhaustion; biosensing; chronic disease; immunophenotyping; machine learning
    DOI:  https://doi.org/10.1021/acssensors.6c02987
  10. Front Oncol. 2026 ;16 1896937
      Emerging evidence demonstrates that tumor metabolic reprogramming not only supports tumor-cell proliferation but also promotes the establishment of an immunosuppressive tumor microenvironment (TME) by altering nutrient competition and metabolite accumulation. Therefore, metabolic reprogramming and immune evasion should be regarded as closely interconnected processes rather than independent phenotypes. By altering the metabolite composition of the TME and local metabolic programs, tumor metabolic reprogramming suppresses immune activation and shapes immune-cell function and fate, thereby promoting cancer immune evasion. This review focuses on two mechanistically developed axes linking tumor metabolism to immune suppression: glycolysis-associated lactate accumulation and lactylation, and nutrient competition involving amino acids and lipids. We summarize how lactate acts as both a metabolic substrate and signaling mediator, how lactylation translates metabolic changes into epigenetic regulation of immune-related transcriptional programs, and how depletion of glutamine, tryptophan, and arginine, together with lipid accumulation and remodeling, impairs effector-cell metabolic fitness while favoring regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells. We further examine hypoxia as a contextual amplifier, the immune-evasion outcomes and reciprocal feedback circuits produced by these alterations, and therapeutic strategies targeting the metabolism-immunity axis. Particular attention is given to context-dependent effects and evidence maturity, because lactate-, hypoxia-, and metabolite-associated pathways are not uniformly immunosuppressive across cell types and conditions. Although preclinical findings support interventions targeting lactate production or transport, lactylation-associated regulators, amino acid metabolism, and the ecto-5'-nucleotidase (CD73)-adenosine axis, clinical evidence remains limited and heterogeneous. Biomarker-guided patient selection, confirmation of target engagement, preservation of immune-cell metabolic fitness, and rational combination strategies will be essential for clinical translation.
    Keywords:  clinical translation; combined therapy; immune evasion; immunosuppressive microenvironment; metabolic reprogramming; metabolism-immunity axis; tumor microenvironment; tumor progression
    DOI:  https://doi.org/10.3389/fonc.2026.1896937
  11. Front Immunol. 2026 ;17 1922207
      Most prior studies on immune-related fatty liver disease have focused on changes in immune cell quantity and composition. However, this "cell-count model" does not fully explain the regional onset of fibrosis, spatial heterogeneity of lesions, or variable immunotherapy responses. Immune dysregulation in metabolic dysfunction-associated steatotic liver disease (MASLD) involves not only compositional changes but also spatial redistribution and functional alterations of immune cells within specific hepatic lobule regions. Emerging multi-omics and spatial transcriptomic data suggest that chemokine gradient remodeling, metabolic microenvironment reprogramming, and circadian rhythm disruption may drive immune cell relocation along the portal-central axis. We propose that immune dysregulation in MASLD reflects a disruption of spatial immune homeostasis and introduce the liver lobule as the basic unit for spatial immune analysis. The lobule comprises three functionally distinct zones: the periportal zone (zone 1), which serves as the primary immune surveillance barrier; the pericentral zone (zone 3), characterized by metabolic stress and functional impairment; and the fibrotic septum, which in advanced disease creates a structurally confined immunosuppressive niche. To quantify regional T cell dysfunction, we propose a Regional Exhaustion Index (REI) as a conceptual framework, calculated as the ratio of PD-1+TIM-3+ CD8+ T cells to total CD8+ T cells within a defined microanatomical region. This metric translates regional immune conditions into a quantifiable measure of T cell functional impairment across different lobular zones. We outline how chemokine remodeling, metabolic reprogramming, and circadian disruption drive spatially distinct immune alterations: reduced immune surveillance in zone 1, functional impairment in zone 3, and structural confinement in the fibrotic septum. We also discuss the translational potential of this framework for biomarker discovery, patient stratification, and targeted therapy. The REI remains an exploratory metric requiring validation of its biological meaning and clinical utility. Current evidence is largely correlational, and the causal role of spatial immune changes in disease progression demands further investigation. Nonetheless, this spatial perspective complements existing paradigms and may guide the development of spatially targeted therapeutic strategies.
    Keywords:  immune exhaustion; liver lobule partitioning; macrophage heterogeneity; metabolic dysfunction-associated steatotic liver disease; regional exhaustion index; spatial immunology
    DOI:  https://doi.org/10.3389/fimmu.2026.1922207
  12. Adv Sci (Weinh). 2026 Sep 16. e77564
      Antigen-loss variants (ALVs) are a major cause of relapse following chimeric antigen receptor (CAR) T cell therapy, particularly in solid tumors where antigen heterogeneity and immune suppression prevail. By integrating public single-cell RNA sequencing analysis with experimental validation, we identify the transcription factor FOXP1 as a critical brake limiting Th9 CAR-T cell differentiation and effector programming. FOXP1 knockdown reprograms Th9 CAR-T but not Tc9 cells toward a metabolically active, cytotoxic, and exhaustion-resistant phenotype, thereby enhancing their persistence and antitumor activity. CUT&Tag and transcriptomic profiling reveal that FOXP1 binds regulatory regions of Il9, Spi1, and Runx1, as well as effector loci such as Tnf and Gzmb, repressing both Th9-lineage and TCR-downstream transcriptional programs. Its depletion releases this repression, broadly activating MAPK, PI3K-Akt/mTOR, and NF-κB pathways that sustain cytokine production and memory formation. Functionally, FOXP1-deficient Th9 CAR-T cells eradicate both antigen-positive and antigen-loss tumor populations by recruiting dendritic cells and promoting endogenous CD8+ T cell clonal expansion via the CD6-Flt3L axis. Our findings establish FOXP1 as a transcriptional checkpoint integrating cytokine and signaling networks to control Th9 CAR-T cell function and provide a mechanistic rationale for engineering CAR-T therapies capable of overcoming antigen escape.
    Keywords:  FOXP1; Th9 CAR T cells; antigen escape
    DOI:  https://doi.org/10.1002/advs.77564
  13. Mol Cancer. 2026 Sep 07. pii: 216. [Epub ahead of print]25(1):
      Treatment with adoptively transferred T cells is challenged by limited longevity of therapeutic cells within tumors. To enhance the durability of anti-tumor T cell products, we have created T cell receptors (TCRs) with built-in co-stimulatory molecules. We observed that TCRs coupled to ICOS mediated exceptionally long-term responses, including delay of tumor recurrence and cures in a mouse melanoma model. TCR:ICOS T cells showed enhanced and antigen-specific production of inflammatory cytokines, enrichment for a stem-like state and resistance to exhaustion. TCR:ICOS-mediated activation of PI3K and NFκB, yet restrained activation of AKT. Genetic ablation of the ICOS-PI3K pathway neutralized the long-term anti-tumor effects. To translate TCR:ICOS to human T cells, we identified a single amino acid change in the cytosolic tail which enabled functional surface expression without proneness to TCR mispairing nor competition for CD3. Notably, the optimized receptor sustained functional performance of human T cells upon repeated stimulation across multiple tumor antigens. Collectively, we present a novel and uniformly applicable TCR:ICOS format that supports fitter T cell products for adoptive cell therapy.
    Keywords:  Adoptive T cell therapy; Co-stimulatory TCR; Differentiation of T cells; Exhaustion of T cells; Gene engineering; Inflammation; Solid tumors
    DOI:  https://doi.org/10.1186/s12943-026-02765-9
  14. Sci Transl Med. 2026 Sep 16. 18(867): eaea3879
      A major natural killer (NK) cell and CD8+ T cell checkpoint is mediated by the inhibitory receptor NKG2A/CD94 and its ligand, human leukocyte antigen E (HLA-E) complexed with nine-amino acid HLA-Ia leader sequence-derived peptides termed VL9 (HLA-E-VL9). Here, we used structure-based design and high-throughput library screening to generate high-affinity antibodies that block NKG2A/CD94 interactions. These antibodies enabled direct NK and CD8+ T cell cytotoxicity and mediated NK cell antibody-dependent cellular cytotoxicity (ADCC). Anti-HLA-E-VL9 antibodies enhanced human NK cell line NK-92 killing of HLA-E-VL9+ human tumors in mice, demonstrating checkpoint inhibition activity in vivo. Moreover, HLA-E-VL9 was found to be expressed on primary human CD4+ T cells infected with HIV in vitro, and its engagement by HLA-E-VL9 antibodies drove elimination of infected cells by NK cell-mediated ADCC. HLA-E-VL9 antibodies also enhanced the killing of HIV-infected cells by NKG2A/CD94+ CD8+ T cells targeting an HIV Rev-derived epitope that complexes with HLA-E. Therefore, anti-HLA-E-VL9 antibodies represent a candidate therapeutic approach to eliminating pathogenic target cells by enhancing both NK cell and CD8+ T cell function and by promoting ADCC.
    DOI:  https://doi.org/10.1126/scitranslmed.aea3879
  15. Cell Rep. 2026 Sep 16. pii: S2211-1247(26)01095-8. [Epub ahead of print]45(10): 118017
      Effector T cell pathogenicity is strongly associated with the progression and severity of autoimmune diseases. Th17 cells are dependent on Ca2+ signaling mediated by the Ca2+ release-activated Ca2+ (CRAC) channels for their effector function. Here, we demonstrate that Th17 cells are uniquely sensitive to temporal inhibition of CRAC channels. Temporal CRAC channel block disturbed the effector functions and metabolic programming of Th17 cells, which were rescued by MYC expression. We uncovered a regulatory hierarchy in which CRAC channel activity during differentiation maintains MYC function by repressing Mxd genes, which antagonize MYC. In an animal model of autoimmunity, temporal CRAC channel block increased MXD expression to attenuate Th17 pathogenicity. These observations extend to human Th17 cells, where temporal CRAC channel blockade also impacts the MYC-MXD axis to impede cytokine production. Collectively, our study identifies a role for CRAC channels in regulating the MYC-MXD balance that governs Th17 effector function.
    Keywords:  CP: immunology; CP: metabolism; CRAC channels; Ca2(+) signaling; MYC-MXD axis; ORAI; autoimmunity; effector T cells; immunometabolism; mitochondrial function in effector T cells
    DOI:  https://doi.org/10.1016/j.celrep.2026.118017
  16. Cell Rep. 2026 Sep 15. pii: S2211-1247(26)01032-6. [Epub ahead of print]45(9): 117954
      Gram-negative pathogens evade immune clearance and promote chronic infections by residing intracellularly. While outer membrane vesicles (OMVs) hold promise as antibacterial vaccine platforms, their clinical potential is limited by lysosomal entrapment of antigens and endotoxin-induced toxicity. Herein, we present an innovative nano-encapsulation strategy to engineer OMVs and overcome these two obstacles. We engineered Porphyromonas gingivalis (P. gingivalis) OMVs by incorporating metal ion adjuvants, coordinated with phenolic ligands, to form a rigid, acid-responsive nanoshell. This shell enhances dendritic cell uptake and promotes lysosomal escape, redirecting antigens to cytosolic cross-presentation and reprogramming CD8+ T cell responses through STING signaling. Nano-encapsulation also attenuates endotoxin-induced systemic cytokine storms, reducing lethality. In murine periodontitis, the engineered OMV vaccine lowers P. gingivalis burden, prevents T cell exhaustion, and mitigates inflammatory tissue damage. These findings provide a safe and effective strategy to counteract immune evasion by intracellular pathogens, with promising potential for immunotherapy against chronic bacterial infections.
    Keywords:  CP: immunology; CP: microbiology; P. gingivalis; PD-1; STING; T cell exhaustion; chronic bacterial infections; intracellular infection; metal-phenolic networks; outer membrane vesicle; periodontitis; vaccine
    DOI:  https://doi.org/10.1016/j.celrep.2026.117954
  17. Front Immunol. 2026 ;17 1818795
      Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by sustained immune activation and fluctuating disease activity. Although exhaustion-associated markers are frequently detected on T cells from patients with SLE, the biological significance of these signatures remains poorly defined. Here, we performed high-dimensional phenotypic profiling of circulating CD8+ and CD4+ T cells from patients with inactive and active SLE using spectral flow cytometry, complemented by an in vitro model of sustained TCR stimulation. We identified distinct T cell subsets characterized by coordinated expression of multiple immune checkpoint receptors, including PD-1, LAG-3, TIM-3, TIGIT and CD39, together with the transcriptional regulator TOX. Notably, checkpoint-enriched populations were preferentially expanded in patients with active disease (aSLE). Despite the accumulation of inhibitory features, both CD8+ and CD4+ T cells retained effector-associated features, including cytokine production and cytotoxic mediator expression, suggesting that immune checkpoint expression in this context is not uniformly associated with the complete loss of effector-associated features characteristic of canonical T cell exhaustion. Trajectory inference of ex vivo datasets, together with the in vitro model, suggested an association between sustained activation and increasing immune checkpoint receptor expression while maintaining the expression of effector-associated molecules. Collectively, these findings identify distinct checkpoint-enriched T cell phenotypic states in SLE, in which immune checkpoint receptor expression coexists with retained effector-associated features. Overall, this work provides a framework for interpreting immune checkpoint-associated T cell phenotypes in systemic autoimmunity.
    Keywords:  T cells; autoimmunity; chronic immune activation; immune checkpoint receptors; systemic lupus erythematosus
    DOI:  https://doi.org/10.3389/fimmu.2026.1818795
  18. Nat Metab. 2026 Sep 18.
      Pancreatic α-cells are central regulators of glucose and amino acid homeostasis, yet the mechanisms that preserve α-cell identity and function remain incompletely understood. N6-methyladenosine (m6A) is a widespread mRNA modification that is essential for β-cell biology and pancreatic endocrine differentiation. Here we show that m6A is a key regulator of α-cell function and plasticity. In α-cells, metabolic cues that stimulate glucagon secretion such as L-arginine increase METTL3, METTL14 and m6A levels. Loss of m6A impairs amino acid-stimulated glucagon secretion, disrupts α-cell identity programmes and induces metabolic rewiring. In mice, α-cell-specific Mettl14 deletion reduces α-cell mass, increases β-cell mass and promotes α-to-β-cell conversion, accompanied by the emergence of late β-like states with features of incomplete maturation. Mechanistically, m6A-eCLIP identifies Yy1 as a direct m6A-sensitive target, and elevated YY1 links m6A loss to signalling rewiring and erosion of α-cell identity. These findings identify m6A as a central regulator of α-cell state and reveal an epitranscriptomic mechanism controlling endocrine cell plasticity.
    DOI:  https://doi.org/10.1038/s42255-026-01591-z
  19. Cytokine Growth Factor Rev. 2026 Sep 12. pii: S1359-6101(26)00064-X. [Epub ahead of print]92 101525
      Metabolic stress-induced immunosuppression begins as early as the precancerous stage in pancreatic ductal adenocarcinoma (PDAC), increases with disease progression, and is characterized by the abundant suppressive myeloid and lymphoid cells. Metabolic adaptation and reprogramming are critical for the survival and function of tumor-infiltrating immune cells. In particular, cytotoxic T cells and natural killer (NK) cells, the stalwarts of cell-mediated immunity, often fail to adapt to the metabolically distinct pancreatic tumor microenvironment (TME) and thus perform antitumor activities poorly, leading to immune exhaustion, aggressive disease progression, metastasis, and poor immunotherapy outcomes. This review article explores the intricate metabolic-immune crosstalk, mediated by tumor microenvironment-associated factors, that impacts the metabolic fitness and effector functions of infiltrating immune cells, including cytotoxic T cells, NK cells, and myeloid cells that bridge innate and adaptive immunity. In addition, we discuss how genetic, molecular, and stromal factors drive metabolic alterations in nutrient-deficient pancreatic tumors, leading to immune cell dysfunction, impaired cytokine release, and poor antitumor immunity. This review further emphasizes the selective targeting of metabolic stress-driven immunosuppressive pathways, unresolved questions, and future directions, including how spatial nutrient gradients across the TME shape distinct regional immune phenotypes, how metabolic interactions with tumor and immune cells occur, and how tumor-selective metabolic therapies could be engineered to exploit features such as hypoxia and acidosis. Understanding these metabolic interactions is crucial for advancing personalized immunotherapy approaches, including immune checkpoint blockade therapies, CAR-T, and other adoptive immune cell therapies, which could improve clinical outcomes in PDAC patients.
    Keywords:  And T cell exhaustion.; CAR-T cells; Immune metabolism and metabolic reprogramming; Immunotherapy resistance; Pancreatic cancer; Stroma modulation
    DOI:  https://doi.org/10.1016/j.cytogfr.2026.08.005
  20. Redox Biol. 2026 Sep 09. pii: S2213-2317(26)00387-3. [Epub ahead of print]97 104388
      Adoptive T cell therapy faces significant hurdles in solid tumors due to the immunosuppressive tumor microenvironment (TME), wherein aberrant accumulation of reactive oxygen species (ROS) serves as a critical driver of therapeutic resistance. Conventional systemic antioxidant strategies are constrained by their non-selectivity and potential to disrupt physiological ROS signaling. Here, we systematically delineate the inherent heterogeneity among T cell subsets-including effector, memory, and regulatory T cells-with respect to metabolic preferences, mitochondrial dynamics, and antioxidant gene expression, revealing their divergent susceptibilities to oxidative stress. Furthermore, the intricate interplay between ROS and diverse immune subsets within the TME, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), collectively orchestrates an immunosuppressive network that underscores the imperative for selective intervention. Building upon this foundation, we propose a multi-layered intervention framework encompassing: (i) reinforcement of intrinsic antioxidant defenses; (ii) metabolic reprogramming to potentiate redox capacity; and (iii) nanomaterial-based remodeling of the pro-oxidative microenvironment. Notably, we introduce the first combinatorial framework centered on nanomaterial-enabled TME modulation integrated with T cell-intrinsic orchestration-a strategy rationally designed to synergistically preserve stem-like memory phenotypes and augment antitumor persistence through multidimensional redox regulation. This framework emphasizes the profound coupling between metabolic and redox homeostasis while critically addressing current challenges, including cellular selectivity, therapeutic windows, and the risk of reductive stress. By providing an integrated mechanistic roadmap and a clear translational trajectory, this review aims to guide future efforts toward subset-selective interventions, spatiotemporally controlled redox modulation, and synergistic integration with existing immunotherapies, ultimately advancing adoptive T cell therapy for solid tumors.
    Keywords:  Adoptive T cell therapy; Antioxidant capacity; Cancer immunotherapy; Reactive oxygen species; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.redox.2026.104388
  21. Immunother Adv. 2026 ;6(1): ltag014
       Introduction: Virus-specific T cell therapy is a promising treatment for life-threatening viral infections following allogeneic hematopoietic stem cell transplantation. However, its efficacy is limited by apoptotic cell loss during in vitro expansion and the cryopreservation process.
    Materials and methods: Human virus-specific T cells were expanded in vitro with interleukin-7 and interleukin-15 in RPMI 1640-based medium with or without L-arginine supplementation, and their survival, phenotype, mitochondrial function, and cytokine signaling were evaluated.
    Results: Supplementation of the culture medium with L-arginine enhanced the survival of human virus-specific T cells during in vitro expansion. Supplementation of the RPMI 1640-based culture medium with L-arginine reduced apoptosis and was accompanied by increased expression of the anti-apoptotic protein MCL-1 in virus-specific CD8+ T cells. In parallel, modest differences in exhaustion- and differentiation-associated markers were observed. Consistent with these survival-associated changes, preservation of mitochondrial membrane potential was concurrently observed in non-apoptotic CD8+ T cells. Among several culture-associated factors that may contribute to mitochondrial preservation, L-arginine availability was associated, at least in part, with common gamma-chain cytokine-induced phosphorylation of mammalian target of rapamycin signalling and signal transducer and activator of transcription 5 downstream of interleukin-7 and interleukin-15 during in vitro culture.
    Conclusion: Together, these findings support L-arginine supplementation as a simple and clinically applicable strategy to enhance the durability of virus-specific T cell products during in vitro expansion, as well as cryopreservation and thawing.
    Keywords:  L-arginine; MCL-1; apoptosis; cytokine signaling; virus-specific T-cell therapy
    DOI:  https://doi.org/10.1093/immadv/ltag014
  22. Nat Commun. 2026 Aug 15. pii: 9811. [Epub ahead of print]17(1):
      The activation and function of CD8+ T cells, which are central for anti-tumor immunity, are tightly regulated by extracellular and intracellular signaling pathways. Dual-specificity phosphatases (DUSP), including DUSP4, dephosphorylate serine/threonine and tyrosine residues of proteins to modulate cellular signaling. Here, we investigate the role of DUSP4 in cancer immunity. Patients with colorectal cancers (CRC) with lower DUSP4 expression across the CRC tissue exhibit shorter survival compared to those with higher DUSP4 expression. By contrast, in AOM/DSS-induced male mouse CRC models, global DUSP4 deficiency enhances tumorigenesis and compromises CD8+ T cell-mediated anti-tumor immunity. Mechanistically, DUSP4 knockout increases ERK2-mediated expression of the T cell activation regulator Klf2, thereby suppressing KLF2-mediated cytotoxic programs. In a CD19+ CRC xenograft mouse model, CRISPRa-mediated DUSP4 activation promotes anti-CD19 CAR-T cell proliferation and anti-tumor cytotoxicity. Thus, our data show that DUSP4 supports CD8+ T cell cytotoxic functions and suggest that DUSP4 may be a promising therapeutic target for enhancing anti-tumor immunity.
    DOI:  https://doi.org/10.1038/s41467-026-76779-8
  23. Nat Commun. 2026 08 17. pii: 9839. [Epub ahead of print]17(1):
      Programmed cell death protein 1 (PD-1) is expressed by T cells during progressive multifocal leukoencephalopathy (PML), a life-threatening brain disease caused by the human-only JC polyomavirus (JCPyV). PD-1 checkpoint immunotherapy has benefited some PML patients, but reasons for its variable outcomes are unclear. Using mouse polyomavirus (MuPyV), we show that PD-1 loss acts in a brain-autonomous manner to increase the magnitude of brain-infiltrating CD4+ and CD8+ T cells and the function of virus-specific CD8+ T cells; in concert, brain virus levels decline and neuroinflammation increases. Deletion of PD-1 in CD4+ T cells, but not CD8+ T cells, recapitulates effects of global PD-1 loss. Single-cell RNA sequencing shows that PD-1-deficient CD8+ T cells cluster as effectors while transcripts associated with proliferation and function are upregulated with loss of PD-1. Thus, CD4+ T cell-intrinsic PD-1 signaling balances antiviral defense against neural injury during polyomavirus infection of the brain.
    DOI:  https://doi.org/10.1038/s41467-026-76762-3
  24. Cancers (Basel). 2026 Sep 01. pii: 2818. [Epub ahead of print]18(17):
      Mitochondria are increasingly recognized as dynamic regulators of cancer-cell adaptation, immune function, and therapeutic response. Beyond their canonical role in energy production, mitochondrial metabolism, dynamics, quality control, and stress signaling influence tumor-cell survival and the capacity of immune effector cells to sustain antitumor activity within the tumor microenvironment. In this narrative review, we examine mitochondrial fitness as a multidimensional functional property encompassing bioenergetic capacity, metabolic flexibility, redox homeostasis, mitochondrial quality control, and adaptation to cellular and therapeutic stress. We propose the mitochondrial functional immune checkpoint as a conceptual framework linking mitochondrial fitness in malignant and immune cells to tumor-immune interactions and immunotherapy response. We discuss how mitochondrial metabolic plasticity, mitochondrial stress and mtDNA signaling, reactive oxygen species, mitochondrial dynamics, and intercellular mitochondrial transfer contribute to immune escape and treatment resistance. We further examine the relevance of mitochondrial fitness to immune checkpoint blockade, CAR-T-cell therapy, and T-cell-redirecting bispecific antibodies, with particular attention to hematological malignancies, including acute myeloid leukemia and multiple myeloma, while incorporating selected evidence from solid tumors to highlight shared mitochondrial mechanisms and their broader oncologic relevance. Finally, we discuss emerging strategies for mitochondrial targeting and functional mitochondrial profiling and their potential integration with established molecular and measurable residual disease assessments. Current evidence supports mitochondrial biology as a complementary dimension of precision oncology, although important challenges remain regarding context dependence, biomarker standardization, therapeutic selectivity, and preservation of immune-cell fitness. Prospective studies are needed to determine whether functional mitochondrial profiling can improve patient stratification and guide rational therapeutic combinations that selectively exploit tumor mitochondrial vulnerabilities while preserving effective antitumor immunity.
    Keywords:  CAR-T cells; T-cell exhaustion; bispecific antibodies; cancer metabolism; immune escape; immunotherapy; mitochondria; oxidative phosphorylation; precision oncology; tumor microenvironment
    DOI:  https://doi.org/10.3390/cancers18172818
  25. Biochim Biophys Acta Rev Cancer. 2026 Sep 14. pii: S0304-419X(26)00188-5. [Epub ahead of print]1881(6): 189716
      Antigen-presenting cells (APCs) translate tumor-derived signals into adaptive immune responses, yet their function is shaped by the metabolically hostile tumor microenvironment (TME). Hypoxia, acidosis, nutrient scarcity, and immunoregulatory metabolite accumulation can reprogram myeloid APC metabolism, impair antigen processing and presentation, weaken costimulatory signaling and cytokine production, and compromise antitumor T cell responses. In this review, we examine how glucose, lipid, amino acid, and mitochondrial metabolic perturbations drive subset-specific remodeling of dendritic cells and tumor-associated macrophages. We emphasize mechanistic links between defined metabolic stressors, discrete antigen-presentation defects, and downstream immune consequences, while framing APC dysfunction as context-dependent adaptive remodeling rather than passive metabolic collapse. We also distinguish impaired lymph-node priming from maladaptive intratumoral restimulation and discuss therapeutic strategies that remodel the TME, recalibrate APC-intrinsic metabolism, enhance targeted delivery, and engineer APC-like cellular functions. Together, these insights position APC immunometabolism as a potentially actionable determinant of tumor immune escape and therapeutic responsiveness.
    Keywords:  Cancer immunotherapy; Dendritic cells; Immunometabolism; Myeloid antigen-presenting cells; Tumor microenvironment; Tumor-associated macrophages
    DOI:  https://doi.org/10.1016/j.bbcan.2026.189716
  26. Sci Bull (Beijing). 2026 Sep 04. pii: S2095-9273(26)01015-7. [Epub ahead of print]
      Adoptive cell transfer (ACT) has achieved durable clinical responses in hematological malignancies, yet remains limited in solid tumors owing to poor T cell infiltration, inadequate persistence, and tumor-driven immunosuppression. Here, we report a bio-orthogonally engineered probiotic-T cell chimera (T-FOLactis) that creates a mutually reinforcing cellular-microbial system, in which FOLactis, an engineered Lactococcus lactis expressing a Flt3L-OX40L fusion protein, provides localized immunostimulatory cues to enhance T cell activation and effector function, while adoptively transferred T cells serve as cytotoxic effectors and mobile carriers that facilitate delivery of the bacterial payload to the tumor microenvironment. Using strain-promoted azide-alkyne cycloaddition chemistry, FOLactis bacteria were covalently anchored onto the surface of T cells, generating a cell-bound platform for spatially restricted immune modulation. In syngeneic colorectal cancer models, T-FOLactis reduced tumor burden by 78.1% compared with saline-treated controls and by 65.0% relative to conventional ACT, while prolonging median survival from 22 to 46 d without overt systemic toxicity. Mechanistically, T-FOLactis promoted dendritic cell (DC)-T cell proximity and established a spatially organized immune-licensing niche that amplified the functional impact of FOLactis-induced inflammatory cues, including IL-18. This spatial configuration was associated with enhanced coupling of cytokine availability, DC maturation, local co-stimulation and cytotoxic CD8+ T cell effector programming. IL-18 blockade impaired this licensing program and reduced therapeutic benefit, supporting IL-18 as a key functional mediator within the DC-T cell licensing niche. Together, these findings establish a modular cell-surface engineering strategy for augmenting ACT in colorectal cancer through coordinated immune network engagement.
    Keywords:  Adoptive cell therapy; Bio-orthogonal click chemistry; Cell-surface engineering; Engineered probiotics; Tumor microenvironment remodeling
    DOI:  https://doi.org/10.1016/j.scib.2026.09.009
  27. FASEB J. 2026 Sep 30. 40(18): e72290
      Cancer-associated fibroblasts (CAFs) are pivotal stromal component in tumor microenvironment (TME) and participate in regulating tumor development and progression via exosomes (exos) mediated intercommunication. However, the intricate mechanism underlying the exosomal miRNAs from CAFs in gastric cancer (GC) tumorigenesis remains ambiguous. Herein, we found that miR-4435 was highly expressed in both CAFs- derived exos and GC tissues and was associated with TNM stage as well as tumor size in GC patients. Additionally, inhibition of miR-4435 remarkably restricted GC proliferation, migration, and invasion in vitro and in vivo; whereas facilitating ferroptosis in GC cells. Moreover, miR-4435 could bind with the downstream target NDUFA10 mRNA and was shown to silence NDUFA10 expression. Importantly, exosomal miR-4435 derived from CAFs could suppress CD8+ T cells effector function, contributing to immune resistance, while knockdown of miR-4435 in CAFs-exo could foster CD8+ T cells effector function and enhanced the sensitivity of anti-PD-1 therapy in GC. Collectively, exosomal miR-4435 derived from CAFs suppress ferroptosis and CD8+ T cell effector function in GC via mediating NDUFA10. Our results highlight exos-transfered miR-4435 as a potential therapeutic target in GC.
    Keywords:  CD8+ T cell effector function; cancer‐associated fibroblasts; exosomes; ferroptosis; gastric cancer; miR‐4435
    DOI:  https://doi.org/10.1096/fj.202602170R
  28. EMBO Rep. 2026 Sep 15.
      Cyclic nucleotides cAMP and cGMP are potent suppressors of immune activation, yet how their intracellular levels are regulated within antigen-presenting myeloid cells remains undefined. Here we identify phosphodiesterase 1B (Pde1b) as a lineage-restricted regulator of cyclic nucleotide signaling in conventional type 1 dendritic cells (cDC1) and a subset of macrophages. Using genetic loss-of-function models and Listeria infection, we show that Pde1b is required for immune responses. Pde1b deficiency impairs bacterial clearance and reduces antigen-specific CD8+ and CD4 + T cell expansion, while myeloid transcriptional programs are skewed towards alternative and immunoregulatory states. These defects are largely attributable to DC dysfunction, as adoptive transfer of wild-type DC in Pde1b-deficient recipients partially rescues T cell priming. Macrophages exhibit parallel defects, including reduced frequency and impaired inflammatory and antimicrobial function. Mechanistically, Pde1b loss elevates cAMP and cGMP in cDC1 and macrophages, leading to increased PKA/PKG signaling and CREB-associated transcriptional reprogramming. Pharmacological inhibition of other phosphodiesterase families does not fully recapitulate Pde1b loss. Together, these findings identify Pde1b as a cell-type-specific regulator of cyclic nucleotide signaling essential for immune responses.
    DOI:  https://doi.org/10.1038/s44319-026-00924-z
  29. J Pharmacol Exp Ther. 2026 Aug 14. pii: S0022-3565(26)01210-3. [Epub ahead of print]393(10): 105010
      Chronic human immunodeficiency virus (HIV) infection results in a persistent state of neuroinflammation, even with combined antiretroviral therapy. Neuroinflammation contributes to pathology termed HIV-associated neurocognitive disorder, which is exacerbated by interferon gamma (IFNγ)-producing CD8+ T cells in the central nervous system. Many people living with HIV self-report using Cannabis sativa to mitigate symptoms of chronic infection and side effects of treatment. C. sativa is composed of various phytocannabinoids, including Δ9-tetrahydrocannbinol (THC), which possesses immune-modulating properties. This study aims to determine whether C. sativa use by people living with HIV, and specifically THC, affects IFNγ secretion by CD8+ T cells. We found that HIV status does not influence T cell IFNγ responses, and C sativa use modestly reduces the average secretion of IFNγ by CD8+ T cells from HIV+ donors. Treatment of CD8+ T cells with THC and the selective cannabinoid receptor 2 agonist, JWH-015, reduced T-cell cytokine secretion, with THC eliciting greater suppression than cannabidiol. These results suggest that THC treatment does not directly impair IFNγ gene expression or protein production, as determined by polymerase chain reaction and flow cytometry. However, THC treatment impaired CD8+ T cell differentiation into IFNγ-competent CD45RO+ cells. These studies are of clinical relevance because reduction of CD8+ T-cell-derived IFNγ in the central nervous system may improve cognitive outcomes during HIV infection. Furthermore, these findings may be generalizable to other inflammatory diseases in which IFNγ-producing CD8+ T cells have been implicated. SIGNIFICANCE STATEMENT: Δ9-Tetrahydrocannbinol (THC) treatment reduces CD8+ T cell interferon gamma (IFNγ) secretion isolated from HIV- and HIV+ individuals. THC and the selective cannabinoid receptor 2 agonist, JWH-015, both reduced CD8+ T cell secretion of IFNγ, interleukin 2, and tumor necrosis factor α, suggesting the involvement of cannabinoid receptor 2. Although THC treatment does not suppress IFNγ mRNA or protein levels, it reduces the number of IFNγ-secreting cells by impairing CD8+ T-cell differentiation into IFNγ-competent CD45RO+ cells.
    Keywords:  CD8(+) T cells; Cannabinoids; Human immunodeficiency virus
    DOI:  https://doi.org/10.1016/j.jpet.2026.105010
  30. Sci Immunol. 2026 Sep 18. 11(123): eaea4179
      Tumor cells often evade immune pressure via metabolic reprogramming, yet the key metabolic regulators orchestrating this process remain incompletely defined. Here, using in vivo metabolic CRISPR screening under distinct immune pressures, we identified tumor cell-intrinsic solute carrier family 1 member 5 (SLC1A5) as a metabolic node that sustains an immunosuppressive tumor microenvironment. SLC1A5-mediated glutamine metabolism in tumor cells modulated CD8 T cell infiltration and effector function, reshaping tumor responses to immune checkpoint blockade therapy. Glucose deprivation up-regulated SLC1A5 isoforms in tumor cells, enhancing glutamine uptake and glutathione synthesis. This adaptation limited mitochondrial oxidative stress and cytosolic mitochondrial DNA release, thereby suppressing cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) activation, interferon-β production, and CD8 T cell antitumor responses. These findings define a glutamine-fueled metabolic program as a barrier to tumor immunogenicity, positioning SLC1A5 as a tumor-intrinsic metabolic regulator with potential therapeutic relevance.
    DOI:  https://doi.org/10.1126/sciimmunol.aea4179
  31. Front Immunol. 2026 ;17 1916577
      Chronic non-infectious uveitis (NIU) is a vision-threatening inflammatory disease in which relapses often occur despite corticosteroids, conventional immunosuppression, and biologic therapy. A growing body of experimental and human evidence indicates that disease persistence is not explained solely by transient effector inflammation. Instead, autoreactive memory CD4+ T cells can survive after the initiating trigger and retain retinal antigen responsiveness, sustaining persistent inflammation and reinitiating acute flares and exacerbations. In experimental chronic autoimmune uveitis, a specific subset of CD44hiIL-7R+IL-15R+ memory CD4+ T cells is maintained in the retina and peripheral secondary lymphoid organs (SLO), while additional autoreactive memory cells can persist in bone marrow niches through signal transducer and activator of transcription 3 (STAT3)-dependent mechanisms. Human studies further show expansion of memory and T helper 17 (Th17)-associated CD4+ T cell populations in NIU; however, the dominant immune cell subsets, clonotypes, and cytokine programs vary among heterogeneous clinical entities of NIU. This review summarizes how memory CD4+ T cells are generated, maintained, and linked to ocular tissue injury, with emphasis on their effector functions, IL-7 and IL-15-dependent survival signaling, STAT3-linked persistence, trafficking, and failed control by ocular immune regulation. We further discuss memory-directed therapeutic concepts grouped as disruption of survival/signaling, restraint of trafficking, and immune tolerization or restoration of ocular immune privilege. We propose the hypothesis that, in NIU subsets demonstrably sustained by pathogenic memory CD4+ T cells, durable remission may require elimination, restraint, or reprogramming of this reservoir rather than suppression of downstream cytokines alone.
    Keywords:  IL-15; IL-23; IL-7; JAK-STAT; chronic uveitis; memory CD4+ T cells; non-infectious uveitis; ocular immune privilege
    DOI:  https://doi.org/10.3389/fimmu.2026.1916577
  32. Sci Adv. 2026 Sep 18. 12(38): eaeg6398
      Metal ions are increasingly recognized as regulators of immune function, yet their application in cancer immunotherapy remains underexplored. Here, we identified cobalt ions (Co2+) as potent suppressors of IFN-γ-induced IDO1 expression through systematic screening of biologically relevant metal ions. Across multiple cancer cell lines, Co2+ notably reduced IDO1 expression and kynurenine production. Mechanistically, Co2+ destabilized IFNGR1 and inhibited IFN-γ-JAK-STAT1 signaling, thereby restoring kynurenine/tryptophan metabolic balance and alleviating immunosuppression of CD8+ T cell. These effects reprogrammed the immunosuppressive tumor microenvironment toward enhanced cytotoxic T cell activity. To minimize the toxicity associated with free Co2+, we developed ConaHA, a hyaluronic acid-based nanoparticle platform enabling sustained and tumor-targeted cobalt delivery. ConaHA enhanced cobalt-mediated immune checkpoint blockade in vivo, resulting in notably improved antitumor efficacy in subcutaneous Panc02, MC38, and B16F10 tumor models and KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) models. Collectively, these findings reveal a previously unrecognized immunoregulatory role of Co2+ and establish a promising framework for metalloimmunotherapy through modulation of metal-immune signaling pathways.
    DOI:  https://doi.org/10.1126/sciadv.aeg6398
  33. Arch Toxicol. 2026 Sep 15.
      Human leukocyte antigen (HLA) alleles are among the strongest genetic risk factors for idiosyncratic drug toxicity. HLA-A*31:01 is a risk factor for carbamazepine (CBZ)-induced delayed drug hypersensitivity, yet allele carriage alone is insufficient for disease development. CD8+ T cells are implicated in these reactions; however, their activation mechanism remains unclear. Using HLA-A*31:01 knock-in (A31-KI) mice, we investigated whether CBZ exposure elicited CD8+ T-cell responses in vivo. The mice received CBZ for 7 days by oral administration (300 mg/kg/day) and auricular application (25 mg/kg/day). CBZ alone did not induce clear CD8+ T-cell activation. Under CD4+ T-cell depletion, CBZ markedly increased programmed cell death protein 1 (PD-1) expression in CD44highCD62Llow CD8+ T cells, suggesting PD-1-mediated restraint of CBZ-responsive activation. Subsequent PD-1 blockade enhanced CD8+ T-cell activation in auricular lymph nodes and induced skin inflammation with elevated serum thymus and activation-regulated chemokine; both were attenuated by CD8+ T-cell depletion. To clarify how CBZ activated CD8+ T cells, we performed ex vivo analyses using splenocytes. CBZ (50 µM) induced proliferation of CD44highCD8+ T cells, whereas this response was absent in purified CD8+ T-cell cultures and reduced by HLA class I and costimulatory blockade, supporting an antigen-presenting cell-dependent mechanism. Collectively, CBZ can activate CD8+ T cells; however, this response is restrained and remains latent. When immune control is disrupted, particularly in an HLA-A*31:01-bearing host, the response can progress to a CD8+ T cell-dependent inflammatory phenotype. Thus, A31-KI mice provide an in vivo platform for understanding CBZ-associated idiosyncratic toxicity and pathogenesis.
    Keywords:  CD8+ T cells; Carbamazepine; Drug hypersensitivity; HLA-A*31:01; Idiosyncratic drug toxicity; Immune regulation
    DOI:  https://doi.org/10.1007/s00204-026-04536-3
  34. J Genet Eng Biotechnol. 2026 Sep;pii: S1687-157X(26)00121-6. [Epub ahead of print]24(3): 100777
       BACKGROUND: Terminal exhaustion of CD8+ tumour-infiltrating lymphocytes constrains the benefit of immune-checkpoint blockade in hepatocellular carcinoma (HCC). The orphan nuclear receptor NR4A2 (Nurr1) belongs to a transcription-factor family implicated in murine T-cell exhaustion, yet its behaviour in the human HCC microenvironment has not been characterised across data modalities. We asked whether NR4A2 is specifically coupled to the terminal-exhaustion programme of human HCC CD8+ T cells, and whether that coupling is reflected in chromatin, tissue topography and bulk-tumour outcome data.
    METHODS: We reanalysed publicly available human HCC datasets spanning four modalities: single-cell RNA sequencing (scRNA-seq; GSE149614, GSE98638, GSE151530, GSE125449), single-cell ATAC sequencing (scATAC-seq; GSE227265), imaging-based spatial transcriptomics (10× Xenium human liver-cancer section) and bulk RNA sequencing with overall-survival annotation (TCGA-LIHC). NR4A2 was profiled across cell compartments and, at higher resolution, across CD8+ T-cell states defined from curated exhaustion, progenitor, effector and naïve gene modules. We tested NR4A2-exhaustion coupling at single-cell and pseudobulk level, examined NR4A2 motif accessibility, traced NR4A2 along a diffusion-pseudotime exhaustion axis, evaluated spatial co-localisation of exhausted CD8+ T cells with tumour-associated macrophages (TAMs), benchmarked machine-learning classifiers of the exhausted state, and compared the human NR4A2 co-expression direction with the published NR4A1/2-knockout phenotype. We additionally trained interpretable gradient-boosted-tree models with SHAP attribution to characterise the exhausted and NR4A2-high states, scored a NR4A2 co-expression regulon, related the programme to immunotherapy-relevant signatures, and modelled overall survival using a CD8-infiltration-adjusted exhaustion score.
    RESULTS: NR4A2 was broadly expressed across HCC compartments and was highest in myeloid cells rather than being T-cell restricted; at whole-compartment and bulk-tumour resolution it was not a clean exhaustion marker. At the resolution of CD8+ T-cell states, however, NR4A2 was sharply enriched in terminally exhausted cells (mean 3.62 versus 1.05; Mann-Whitney p ≈ 3.4 × 10-83) and correlated with the exhaustion module (single-cell Spearman ρ = 0.45) but not with the effector module (ρ = 0.06), arguing that NR4A2 is not a generic activation gene. NR4A2 expression increased monotonically along a diffusion-pseudotime axis toward terminal exhaustion (ρ = 0.37). In Xenium tissue, exhausted CD8+ T cells were modestly but significantly enriched in the neighbourhood of TAMs relative to other CD8+ T cells (permutation p = 0.005). The human NR4A2 co-expression direction was 83% concordant with the published NR4A1/2-knockout differential-expression direction. In bulk TCGA-LIHC, NR4A2 was lower in tumour than adjacent liver and only weakly exhaustion-correlated, consistent with hepatocyte-dominated bulk signal and reinforcing the need for compartment-resolved analysis. Interpretable machine learning attributed NR4A2-high status to an immediate-early/AP-1 activation programme, a NR4A2 co-expression regulon was selectively active in exhausted cells, and the programme tracked the T-cell-inflamed phenotype (ρ = 0.87); although raw bulk NR4A2 was non-prognostic, a CD8-infiltration-adjusted exhaustion score independently predicted shorter overall survival (hazard ratio 1.42 per standard deviation, p < 0.001).
    CONCLUSIONS: A NR4A2 co-expression regulon was most active in exhausted cells; explainable modelling linked NR4A2-high status to an immediate-early/AP-1 activation programme; the programme marked immune-hot tumours; and although bulk NR4A2 was non-prognostic, a CD8-infiltration-adjusted exhaustion score was independently associated with worse overall survival (HR 1.42 per SD, p < 0.001). Across four independent data modalities, NR4A2 behaves as a resolution-dependent marker of the terminal-exhaustion programme in HCC CD8+ T cells that is spatially associated with the myeloid niche. The convergence supports NR4A2 as a candidate component of an HCC exhaustion signature and a hypothesis-generating target for functional study, while underscoring that its association is masked in bulk and whole-compartment data.
    Keywords:  CD8(+) T-cell exhaustion; Explainable machine learning (SHAP); Hepatocellular carcinoma; Immune checkpoint blockade; NR4A2; Prognostic signature; Single-cell RNA sequencing; Spatial transcriptomics; Tumour microenvironment
    DOI:  https://doi.org/10.1016/j.jgeb.2026.100777
  35. Cell. 2026 Sep 15. pii: S0092-8674(26)01010-X. [Epub ahead of print]
      The metabolic hallmarks of high-grade glioma (HGG) are not fully understood. Human brain tissue metabolomics revealed that the creatine synthesis pathway intermediate guanidinoacetate (GAA) accumulated ∼100-fold in HGGs relative to controls, which was caused by imbalanced activities of enzymes in this pathway. Glioma cells secreted GAA rather than using it to produce creatine, implicating an alternative function. GAA accumulates in GAA N-methyltransferase (GAMT) deficiency, an inborn error of metabolism, and elevates neuronal excitability. Neuronal excitability is also increased in glioma and drives tumor growth through neuron-glioma interactions. We hypothesized that glioma-generated GAA excites surrounding neurons. Indeed, GAA induced neuronal hyperactivity by activating GABAA receptors and causing depolarizing currents in glioma-associated neurons with dysregulated chloride homeostasis. Depleting tumoral GAA decreased electrochemical activity, neuron-glioma interactions, and tumor aggressiveness. Our findings unveil a mechanism linking cancer metabolism with cancer neuroscience and leverage human genetics to nominate GAA synthesis as a target in gliomas.
    Keywords:  GABA; GAMT deficiency; cancer metabolism; cancer neuroscience; creatine; glioma; guanidinoacetate; inborn error of metabolism; metabolite signaling
    DOI:  https://doi.org/10.1016/j.cell.2026.08.037
  36. Int Immunol. 2026 Sep 16. pii: dxag048. [Epub ahead of print]
      STK11/LKB1 mutations are critical drivers of primary resistance to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC); however, the metabolic mechanisms by which STK11 deficiency remodels the tumor microenvironment (TME) to induce an immunosuppressive state remain largely elusive. By performing metabolomics and liquid chromatography-mass spectrometry (LC-MS) analysis on tumor interstitial fluid (TIF) from STK11-deficient patient-derived xenograft (PDX) and syngeneic mouse CMT167 models, we investigated the metabolic landscape and its impact on CD8+ T cell functionality. We further integrated biochemical assays (ChIP, Co-IP, and dual-luciferase) and engineered small extracellular vesicles (sEVs) to dissect the upstream regulatory network and evaluate therapeutic potential. We identified a significant and specific accumulation of phosphoethanolamine (pEtn) in the STK11-deficient TIF, which directly impairs CD8+ T cell effector functions by downregulating membrane diacylglycerol (DAG) and blocking proximal T cell receptor (TCR) signaling. Mechanistically, STK11 loss triggers mitochondrial reactive oxygen species (ROS) accumulation, which inhibits prolyl hydroxylases (PHDs) and prevents the VHL-mediated degradation of HIF1A. Stabilized HIF1A subsequently recruits the demethylase TET1 to the ETNK2 promoter, driving its epigenetic activation and excessive pEtn synthesis. Clinical analyses confirm that high ETNK2 expression correlates with poor ICI response and shortened survival. Targeted delivery of siETNK2 via EGFR-targeted exosomes effectively lowered TIF pEtn concentrations, restored T cell activity, and sensitized STK11-deficient tumors to PD-1 blockade in vivo. This study elucidates a novel "mitochondrial ROS-HIF1A-TET1-ETNK2" metabolic-epigenetic axis, providing a precise interventional strategy to overcome genotype-specific immune resistance in NSCLC.
    Keywords:  Exosome; Immune checkpoint inhibitor resistance
    DOI:  https://doi.org/10.1093/intimm/dxag048
  37. Cancer Cell. 2026 Sep 17. pii: S1535-6108(26)00394-6. [Epub ahead of print]
      Radiation induces immunosuppressive myeloid cells that drive therapeutic resistance and metastasis. We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy. Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses; spatiotemporal mapping shows that this fate program initiates rapidly in the bone marrow. Mechanistically, a radiation-responsive p53-TET2 axis decreases m5C on chromatin-associated RNAs (caRNAs), enforcing immunosuppressive chromatin compaction and silencing interferon signaling, whereas Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity. Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors. These findings define MDACs as an immunogenic myeloid subset and establish myeloid reprogramming as a strategy to improve radiotherapy-immunotherapy outcomes.
    Keywords:  MDACs; MDSCs; T cell cytotoxicity; TET2; chromatin-associated RNA; immunotherapy; myeloid reprogramming; myeloid-derived activating cells; myeloid-derived suppressor cells; radiotherapy
    DOI:  https://doi.org/10.1016/j.ccell.2026.08.017
  38. Cells. 2026 Aug 28. pii: 1562. [Epub ahead of print]15(17):
      Hepatic inflammation is a defining feature of Metabolic Dysfunction-Associated Steatohepatitis (MASH), yet the specific contributions of individual immune cell populations and their reciprocal interactions remain incompletely understood. In this study, we combined flow cytometry with single-cell transcriptomic profiling to characterize the hepatic immune landscape in a novel model of spontaneous MASH caused by hepatocyte-specific deficiency of endoplasmic reticulum-associated degradation (ERAD). Hepatic ERAD deficiency led to the expansion of multiple immune cell populations in the liver, including CD8+ T cells, macrophages, monocytes, and dendritic cells, accompanied by extensive functional reprogramming of both innate and adaptive immune compartments. Myeloid cells exhibited enhanced phagocytic activity and increased antigen processing and presentation, whereas CD8+ T cells displayed elevated proliferation capacity, DNA repair activity and cytotoxicity. Notably, two functionally distinct triggering receptor expressed on myeloid cells 2 (TREM2)-expressing macrophage subsets emerged during the progression of ERAD deficiency-induced MASH. Depletion of CD8+ T cells increased monocyte infiltration and aggravated liver injury, suggesting that CD8+ T cells exert a previously unrecognized protective role by restraining monocyte recruitment. Collectively, these findings reveal highly coordinated interactions between innate and adaptive cells during MASH progression and identify CD8+ T cells as potential regulators of monocyte infiltration and hepatic injury.
    Keywords:  ERAD; MAFLD; MASH; T lymphocyte; immune cell; immune homeostasis; liver injury; macrophage
    DOI:  https://doi.org/10.3390/cells15171562